In a filing submitted March 18, plaintiffs argue that the drug makers overstated the benefits of GLP-1 drugs while minimizing the risk of serious gastrointestinal injuries, including gastroparesis, ileus, and intestinal obstruction
Clinical trial data demonstrates that most patients who experience nausea or vomiting find these symptoms are transient and mild to moderate in severity
The minimum BMI for semaglutide (Wegovy) under FDA labeling is 30 without any additional conditions, or 27 with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia
Adjunct therapy with glucagon-like peptide 1 receptor agonists could offer benefits in this population of patients by preserving -cell mass and function while also contributing to cardiorenal risk mitigation
Median follow-up reached about 6 years for aspirin users and 7 years for GLP-1 users
She is now suing both Novo Nordisk and Eli Lilly, claiming that they failed to adequately warn about the possible side effects of severe gastrointestinal events (of which she had many, but well get into that in a moment.) Now, Ive read every news report I could find on this story and one thing that is very clear to me is that there are reporters out there who are super confused about these drugs, so instead of just yelling at my computer screen and hoping someone absorbs the information, I thought I would offer a quick explanation to anyone who was confused before, is confused, and/or has become more confused after, reading about this situation
